Search
Aplaviroc
go.drugbank.com/drugs/DB06497InvestigationalA spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.
APD668
go.drugbank.com/drugs/DB05166ExperimentalAPD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal
go.drugbank.com/drugs/DB06124ExperimentalC-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. Calpain is the primary protease that degrades skeletal muscle. … C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal
Fucoxanthin
go.drugbank.com/drugs/DB15462InvestigationalFucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green color. … A clinical trial of fucoxanthin against non-alcoholic fatty liver disease is ongoing.
Riferminogene pecaplasmid
go.drugbank.com/drugs/DB06394InvestigationalRiferminogene pecaplasmid (non-viral fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of human FGF1.
Isoflurane
go.drugbank.com/drugs/DB00753ApprovedInvestigationalVet approvedA stable, non-explosive inhalation anesthetic, relatively free from significant side effects.
Triazolam
go.drugbank.com/drugs/DB00897ApprovedInvestigationalInternationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
IL15-NK Cell
go.drugbank.com/drugs/DB15725InvestigationalIn particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.
R343
go.drugbank.com/drugs/DB06316InvestigationalR343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.